Illumina expanded its Alliance for Genomic Discovery partnerships, adding Alnylam Pharmaceuticals and attracting pharma interest in large, linked genomic‑clinical datasets from biobanks such as Vanderbilt’s BioVU. Illumina now houses more than 250,000 genomes from BioVU and will add 30,000 more samples, positioning the company to offer integrated genomic and clinical datasets for target discovery and translational research. Pharma partners cited utility for human genetics–guided target selection, real‑world data analyses and cross‑team access to cohorts for diverse indications. Illumina also plans to integrate proteomic and other multi‑omic data types, making the platform a potential one‑stop resource for early target validation and biomarker discovery.